Islas ME, Cabrera RA, Morales SR

Language: Spanish
References: 19
Page: 175-179
PDF size: 214.62 Kb.

ABSTRACT

Reumatoid arthritis is a disorder autoimmune of unknown etiology characterized by symmetrical, erosive sinovitis and in some cases implication of extraarticulating, Most of the patients have experience a chronic course of the disease that in spite of the therapy, can give rise to the progressive destruction towards the deformity, until the postration or incapacitation. Methotrexate is one of inmunomoduladores medicines more widely used in reumatoid arthritis and is generally safe in the used meterings. Nevertheless, one is due to be alert with respect to some of its less common indirect effect like the pneumonitis. We present the case of a patient who developed pulmonary toxicity induced by methotrexate and a bibliography review.

REFERENCES

1. Suárez-Almazor ME, Belseck E, Shea B, Wells G, Tugwell P. Methotrexate for treating rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 2 2003.

2. Sáenz Abad D, Ruiz-Ruiz FJ, Monón-Ballarín S, Mozota- Duarte J, Marquina- Barcos A. Neumonitis secundaria a metotrexate. An Med Interna 2008;25:27-30.

3. Fhlliquin P, Renoux M, Perrot S, et al. Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis. British Journal of Rheumatology 1996;35:441-445.

4. Kremer JM, Alarcón GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathology features of methotrexate associated lung injury in patients with rheumatoid arthritis. Arthritis Rheum 1997;40:1829-1837.

5. Alarcon GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis: A multicenter, case-control study. Ann Intern Med 1997;127:356-364.

6. Cho I, Mori S, Imamura F, Kiyofuji C, Sugimoto M. Methotrexate pneumonia lacking dyspnea and radiographic interstitial patterns during treatment for early rheumatoid arthritis: bronchoalveolar lavage and transbronchial lung biopsy in a differential diagnosis. Mod Rheumatol 2007;17:256-261.

7. Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJMed 2001;94:309-319.

8. Scottish Intercollegiate Guidelines Network. Management of early rheumatoid arthritis. A National Clinical Guideline. Publication No. 48. Scottish Intercollegiate Guidelines Network, 2000.

9. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J 2000;15:373-381.

10. Sharma A, Provenzale D, McKusick A, Kaplan MM. Interstitial pneumonitis after low-dose methotrexate therapy in primary biliary cirrhosis. Gastroenterology 1994;107:266-270.

11. Akoun GM, Gauthier-Rahman S, Mayaud CM, et al. Leukocyte migration inhibition in methotrexate-induced pneumonitis. Evidence for an immunologic cell-mediated mechanism. Chest 1987;91:96-99.

12. White DA, Rankin JA, Stover DE, et al. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. Am Rev Respir Dis 1989;139:18-21.

13. Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology 2004;43:143-147.

14. Grove ML, Hassell AB, Hay EM, Shadforth MF. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. Q J Med 2001;94:309-319.

15. Ayushi Sikka. Methotrexate-induced Pulmonary Toxicity. J Indian Acad Clin Med 2006;7(4).

16. Rossi SE, Erasmus JJ, McAdams HP, et al. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-1259.

17. Arakawa H, Yamasaki M, Kurihara Y, et el. Methotrexate induced pulmonary injury: serial CT findings. J Thorac Imaging 2003;18:231-236.

18. Searles G, McKendry RJR. Methotrexate penumonitis in rheumatoid arthritis: potential risk factors. Four cases and review of the literature. J Rheumatol 1987;14:1164-1171.

19. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the Management of Rheumatoid Arthritis 2002 update. Arthritis & Rheumatism 2002;46:328-346.